These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 6970620

  • 1. Progressing Moloney sarcoma virus (M-MSV) induced tumors: effect of host's immunomanipulation.
    Collavo D, Zanovello P, Biasi G, Chieco-Bianchi L.
    Cell Mol Biol Incl Cyto Enzymol; 1980; 26(2):155-8. PubMed ID: 6970620
    [No Abstract] [Full Text] [Related]

  • 2. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V, Lahaye T, Horvath C, Zanovello P, Collavo D, Engers HD.
    Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
    [Abstract] [Full Text] [Related]

  • 3. T cell tolerance in moloney-murine leukemia virus (M-MuLV) carrier mice: low cytotoxic T lymphocyte precursor frequency and absence of suppressor T cells in carrier mice with Moloney-murine sarcoma (M-MSV)-induced tumors.
    Collavo D, Ronchese F, Zanovello P, Biasi G, Chieco-Bianchi L.
    J Immunol; 1982 Feb; 128(2):774-9. PubMed ID: 6459385
    [No Abstract] [Full Text] [Related]

  • 4. Cell-mediated immunity to Moloney sarcoma virus in mice. II. Analysis of antigenic specificities involved in T lymphocyte-mediated in vivo rejection of murine sarcoma virus-induced tumors.
    Gorczynski RM, Knight RA.
    Eur J Immunol; 1975 Feb; 5(2):148-55. PubMed ID: 1086221
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice.
    Kirchner H, Muchmore AV, Chused TM, Holden HT, Herberman RB.
    J Immunol; 1975 Jan; 114(1 Pt 1):206-10. PubMed ID: 122986
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice.
    Collavo D, Zanovello P, Biasi G, Chieco-Bianchi L.
    J Immunol; 1981 Jan; 126(1):187-93. PubMed ID: 6969741
    [Abstract] [Full Text] [Related]

  • 14. Protective effect of immune sera against transplantable Moloney virus-induced sarcoma and lymphoma.
    Pearson GR, Redmon LW, Bass LR.
    Cancer Res; 1973 Jan; 33(1):171-8. PubMed ID: 4734119
    [No Abstract] [Full Text] [Related]

  • 15. T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo.
    Leclerc JC, Cantor H.
    J Immunol; 1980 Feb; 124(2):851-4. PubMed ID: 6243333
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.